NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market Tuesday that its fiscal first quarter revenues grew by 9 percent from the year-ago quarter, beating analysts' consensus top-line estimate. 

The molecular diagnostics firm brought in total revenues of $183.5 million for the three months ended Sept. 30, compared to $168.8 million in Q1 2015, and above the consensus Wall Street estimate of $177.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.

Nov
02
Sponsored by
Qiagen

This webinar will discuss the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.

Dec
05
Sponsored by
Agilent Technologies

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.